Stock BCTX BRIACELL THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BriaCell Therapeutics Corp. Nasdaq

Equities

BCTX

CA1079301091

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.17 USD -3.12% Intraday chart for BriaCell Therapeutics Corp. +7.43% -62.91%
Apr. 24 BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting MT
Apr. 10 BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer CI

Valuation

Fiscal Period: July 2021 2022 2023 2024 2025 2026
Capitalization 1 78.55 101.6 106 34.21 - -
Enterprise Value (EV) 1 78.55 101.6 106 34.21 34.21 34.21
P/E ratio -57.2 x -3.78 x -5.1 x -1.54 x -1.71 x -1.31 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF - - -4,465,638 x - - -
FCF Yield - - -0% - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 15,270 15,518 15,982 15,982 - -
Reference price 2 5.144 6.545 6.635 2.140 2.140 2.140
Announcement Date 10/28/21 10/27/22 10/25/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: July 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - -
EBITDA - - - - - -
EBIT 1 - -15.29 -23.27 -34.4 -33.8 -62.4
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 - -26.84 -20.3 -24.5 -28.75 -52.3
Net income 1 -0.4283 -26.84 -20.3 -24.5 -28.75 -52.3
Net margin - - - - - -
EPS 2 -0.0900 -1.730 -1.300 -1.390 -1.250 -1.640
Free Cash Flow - - -23.74 - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 10/28/21 10/27/22 10/25/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: July 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - -
EBITDA - - - - - - - - - - -
EBIT 1 -3.932 -4.839 -4.226 -5.403 -4.486 -5.677 -7.706 -8.503 -9.829 -7.9 -8.2
Operating Margin - - - - - - - - - - -
Earnings before Tax (EBT) 1 -3.865 -4.839 -15.75 -1.107 -11.88 -4.895 -2.419 5.959 -11.33 -9.4 -9.7
Net income 1 -3.865 -4.839 -15.75 -1.107 -11.88 -4.895 -2.419 6.002 -11.29 -9.4 -9.7
Net margin - - - - - - - - - - -
EPS 2 -0.2400 -0.3200 -1.020 -0.0700 -0.7700 -0.3200 -0.1400 0.3600 -0.7100 -0.5500 -0.4600
Dividend per Share - - - - - - - - - - -
Announcement Date 3/14/22 6/13/22 10/27/22 12/14/22 3/15/23 6/14/23 10/25/23 12/14/23 3/18/24 - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: July 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - -23.7 - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 10/28/21 10/27/22 10/25/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.93
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BCT Stock
  4. BCTX Stock
  5. Financials BriaCell Therapeutics Corp.